Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GMAB – Genmab A/S

Genmab A/S
GMAB
$24.65
Name : Genmab A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,161,499,648.00
EPSttm : 1.93
finviz dynamic chart for GMAB
Genmab A/S
$24.65
0.94%
$0.23

Float Short %

0.58

Margin Of Safety %

-23

Put/Call OI Ratio

0.26

EPS Next Q Diff

-0.17

EPS Last/This Y

0.03

EPS This/Next Y

-0.09

Price

24.65

Target Price

31.54

Analyst Recom

1.78

Performance Q

17.21

Relative Volume

1.06

Beta

0.92

Ticker: GMAB




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25GMAB23.420.480.293447
2025-07-28GMAB23.090.480.003450
2025-07-29GMAB22.60.480.173453
2025-07-30GMAB22.270.480.003454
2025-07-31GMAB21.660.480.423460
2025-08-01GMAB21.770.480.073457
2025-08-04GMAB21.980.480.003469
2025-08-05GMAB22.110.490.003418
2025-08-06GMAB21.540.481.003441
2025-08-07GMAB22.70.480.083459
2025-08-08GMAB21.440.480.333551
2025-08-11GMAB21.080.4812.383555
2025-08-12GMAB21.880.390.003363
2025-08-13GMAB22.710.360.043545
2025-08-14GMAB230.360.053536
2025-08-15GMAB23.30.360.083569
2025-08-18GMAB23.420.250.671453
2025-08-19GMAB23.820.270.011485
2025-08-20GMAB24.080.210.531814
2025-08-21GMAB24.420.220.081825
2025-08-22GMAB24.650.260.261720
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25GMAB23.405.9104.51.34
2025-07-28GMAB23.125.934.61.34
2025-07-29GMAB22.605.9-11.11.34
2025-07-30GMAB22.275.93.21.34
2025-07-31GMAB21.675.9-36.61.34
2025-08-01GMAB21.785.9-28.31.34
2025-08-04GMAB21.985.983.51.34
2025-08-05GMAB22.105.976.11.34
2025-08-06GMAB21.535.9-59.31.34
2025-08-07GMAB22.695.995.81.34
2025-08-08GMAB21.435.9-85.91.34
2025-08-11GMAB21.095.9-27.21.34
2025-08-12GMAB21.8853.271.81.75
2025-08-13GMAB22.6753.2-610.51.75
2025-08-14GMAB23.0053.2-651.01.75
2025-08-15GMAB23.3153.2-689.11.75
2025-08-18GMAB23.4253.2-707.31.75
2025-08-19GMAB23.8253.2-698.91.75
2025-08-20GMAB24.0753.2-693.71.75
2025-08-21GMAB24.4253.2-696.71.73
2025-08-22GMAB24.6553.2-705.81.73
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25GMAB0-0.290.60
2025-07-28GMAB0-0.370.60
2025-07-29GMAB0-0.370.60
2025-07-30GMAB0-0.370.60
2025-07-31GMAB0-0.370.60
2025-08-01GMAB0-0.370.60
2025-08-04GMAB0-0.410.60
2025-08-05GMAB0-0.410.60
2025-08-06GMAB0-0.410.60
2025-08-07GMAB0-0.410.60
2025-08-08GMAB0-0.410.60
2025-08-11GMAB0-0.450.60
2025-08-12GMAB0-0.450.58
2025-08-13GMAB0-0.450.58
2025-08-14GMAB0-0.450.58
2025-08-15GMAB0-0.450.58
2025-08-18GMAB0-0.410
2025-08-19GMAB0-0.410.58
2025-08-20GMAB0-0.410.58
2025-08-21GMAB0-0.410.58
2025-08-22GMAB0-0.410.58
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.54

Avg. EPS Est. Current Quarter

0.44

Avg. EPS Est. Next Quarter

0.37

Insider Transactions

Institutional Transactions

-0.41

Beta

0.92

Average Sales Estimate Current Quarter

6205

Average Sales Estimate Next Quarter

6473

Fair Value

18.93

Quality Score

100

Growth Score

92

Sentiment Score

75

Actual DrawDown %

49.8

Max Drawdown 5-Year %

-63.1

Target Price

31.54

P/E

12.31

Forward P/E

12.89

PEG

1.05

P/S

4.47

P/B

2.86

P/Free Cash Flow

15.08

EPS

2

Average EPS Est. Cur. Y​

1.73

EPS Next Y. (Est.)

1.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.52

Relative Volume

1.06

Return on Equity vs Sector %

-1.5

Return on Equity vs Industry %

11.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.39

EBIT Estimation

-705.8
Genmab A/S
Sector: Healthcare
Industry: Biotechnology
Employees: 2639
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Novo Nordisk A/S
NVO
$56.98
Name : Novo Nordisk A/S
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $246,973,530,112.00
EPSttm : 3.89
finviz dynamic chart for NVO
Novo Nordisk A/S
$56.98
2.76%
$1.53

Float Short %

0.62

Margin Of Safety %

7

Put/Call OI Ratio

0.8

EPS Next Q Diff

5.06

EPS Last/This Y

EPS This/Next Y

0.67

Price

56.98

Target Price

72.72

Analyst Recom

2.15

Performance Q

-16.41

Relative Volume

1.18

Beta

0.64

Ticker: NVO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25NVO71.720.930.39587060
2025-07-28NVO68.990.900.77568017
2025-07-29NVO54.020.900.70575125
2025-07-30NVO50.090.870.58747757
2025-07-31NVO47.090.830.85885071
2025-08-01NVO48.150.810.421011804
2025-08-04NVO48.820.800.781016241
2025-08-05NVO47.270.810.561065077
2025-08-06NVO45.410.801.201111546
2025-08-07NVO48.720.780.441205715
2025-08-08NVO51.080.780.331233303
2025-08-11NVO49.850.790.801161889
2025-08-12NVO49.760.820.451210548
2025-08-13NVO50.90.810.561234114
2025-08-14NVO50.920.811.491245487
2025-08-15NVO52.390.820.201255522
2025-08-18NVO53.810.840.301093936
2025-08-19NVO54.760.800.381140084
2025-08-20NVO54.320.810.461152990
2025-08-21NVO55.460.810.841161573
2025-08-22NVO56.970.800.331175061
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25NVO71.7034.62376.626.02
2025-07-28NVO68.9733.21035.426.04
2025-07-29NVO53.9433.2-3688.726.04
2025-07-30NVO50.0333.2-136.426.04
2025-07-31NVO47.0733.0-1091.825.07
2025-08-01NVO48.1933.0-629.025.07
2025-08-04NVO48.8133.8685.525.04
2025-08-05NVO47.2233.8-264.425.04
2025-08-06NVO45.3733.7-676.324.86
2025-08-07NVO48.7633.71320.824.86
2025-08-08NVO51.08-2.2-2539.624.00
2025-08-11NVO49.85-2.2-3370.124.00
2025-08-12NVO49.78-3.7-3372.224.52
2025-08-13NVO50.90-3.7-2815.624.52
2025-08-14NVO50.92-3.7-2809.924.52
2025-08-15NVO52.40-3.7-2488.124.52
2025-08-18NVO53.77-3.7-1994.924.52
2025-08-19NVO54.78-3.9-2905.324.84
2025-08-20NVO54.31-3.9-1683.824.84
2025-08-21NVO55.46-3.7-1094.624.84
2025-08-22NVO56.98-3.7-2040.824.84
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25NVO0-4.380.70
2025-07-28NVO0-5.270.70
2025-07-29NVO0-5.270.70
2025-07-30NVO0-5.270.70
2025-07-31NVO0-5.270.70
2025-08-01NVO0-5.270.70
2025-08-04NVO0-5.660.70
2025-08-05NVO0-5.660.70
2025-08-06NVO0-5.660.70
2025-08-07NVO0-5.660.70
2025-08-08NVO0-5.660.70
2025-08-11NVO0-5.720.70
2025-08-12NVO0-5.720.62
2025-08-13NVO0-5.720.62
2025-08-14NVO0-5.720.62
2025-08-15NVO0-5.720.62
2025-08-18NVO0-5.780.62
2025-08-19NVO0-5.780.62
2025-08-20NVO0-5.780.62
2025-08-21NVO0-5.780.62
2025-08-22NVO0-5.780.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.97

Avg. EPS Est. Current Quarter

5.89

Avg. EPS Est. Next Quarter

6.03

Insider Transactions

Institutional Transactions

-5.78

Beta

0.64

Average Sales Estimate Current Quarter

77654

Average Sales Estimate Next Quarter

84052

Fair Value

60.77

Quality Score

99

Growth Score

95

Sentiment Score

45

Actual DrawDown %

61.5

Max Drawdown 5-Year %

-68.5

Target Price

72.72

P/E

15.7

Forward P/E

13.53

PEG

1.19

P/S

4.22

P/B

9.57

P/Free Cash Flow

20.21

EPS

3.63

Average EPS Est. Cur. Y​

24.84

EPS Next Y. (Est.)

25.52

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.6

Relative Volume

1.18

Return on Equity vs Sector %

41.4

Return on Equity vs Industry %

33

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

-1.17

EBIT Estimation

-2040.8
Novo Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 78387
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
stock quote shares NVO – Novo Nordisk A/S Stock Price stock today
news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch NVO – Novo Nordisk A/S yahoo finance google finance
stock history NVO – Novo Nordisk A/S invest stock market
stock prices NVO premarket after hours
ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Ascendis Pharma A/S
ASND
$194.30
Name : Ascendis Pharma A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $11,765,720,064.00
EPSttm : -5.28
finviz dynamic chart for ASND
Ascendis Pharma A/S
$194.30
0.78%
$1.50

Float Short %

4.58

Margin Of Safety %

Put/Call OI Ratio

1.36

EPS Next Q Diff

0.98

EPS Last/This Y

5.13

EPS This/Next Y

5.44

Price

194.3

Target Price

249.89

Analyst Recom

1

Performance Q

21.4

Relative Volume

0.65

Beta

0.38

Ticker: ASND




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25ASND167.491.340.107154
2025-07-28ASND164.371.340.057173
2025-07-29ASND163.251.400.027041
2025-07-30ASND167.721.390.447050
2025-07-31ASND173.491.340.067299
2025-08-01ASND174.181.111.137912
2025-08-04ASND184.211.100.497885
2025-08-05ASND186.590.900.6010236
2025-08-06ASND182.890.796.4113321
2025-08-07ASND190.340.785.9814929
2025-08-08ASND191.530.801.0915297
2025-08-11ASND195.790.850.3915475
2025-08-12ASND195.910.850.5815450
2025-08-13ASND190.810.857.8015456
2025-08-14ASND192.020.87301.4015577
2025-08-15ASND198.340.960.3916333
2025-08-18ASND194.011.110.018481
2025-08-19ASND194.31.342.207795
2025-08-20ASND191.921.341.117811
2025-08-21ASND193.81.350.157864
2025-08-22ASND194.131.360.067850
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25ASND167.4731.5117.8-3.71
2025-07-28ASND164.6531.5120.5-3.71
2025-07-29ASND163.3231.5117.6-3.71
2025-07-30ASND166.7831.5111.5-3.71
2025-07-31ASND173.5031.4107.2-3.72
2025-08-01ASND174.4831.4115.6-3.72
2025-08-04ASND184.1531.4104.2-3.72
2025-08-05ASND186.5931.4114.0-3.72
2025-08-06ASND182.7731.4120.6-3.72
2025-08-07ASND190.3531.4105.9-3.72
2025-08-08ASND191.4931.4114.6-3.72
2025-08-11ASND195.8762.8-36.9-2.81
2025-08-12ASND195.7784.459.1-2.28
2025-08-13ASND191.0882.762.7-2.44
2025-08-14ASND191.7682.758.5-2.44
2025-08-15ASND198.2082.754.3-2.39
2025-08-18ASND194.3282.761.9-2.39
2025-08-19ASND194.6282.758.5-2.39
2025-08-20ASND192.7184.360.3-2.46
2025-08-21ASND192.9684.358.7-2.46
2025-08-22ASND194.3084.357.7-2.46
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25ASND0.001.604.55
2025-07-28ASND0.001.524.55
2025-07-29ASND0.001.524.55
2025-07-30ASND0.001.524.55
2025-07-31ASND0.001.524.55
2025-08-01ASND0.001.524.55
2025-08-04ASND0.001.294.55
2025-08-05ASND0.001.294.55
2025-08-06ASND0.001.294.55
2025-08-07ASND0.001.294.55
2025-08-08ASND0.001.294.55
2025-08-11ASND0.001.264.54
2025-08-12ASND0.001.264.58
2025-08-13ASND0.001.264.58
2025-08-14ASND0.001.264.58
2025-08-15ASND0.001.264.58
2025-08-18ASND0.000.404.58
2025-08-19ASND0.000.404.58
2025-08-20ASND0.000.404.58
2025-08-21ASND0.000.404.58
2025-08-22ASND0.000.404.58
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.93

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

0.05

Insider Transactions

Institutional Transactions

0.4

Beta

0.38

Average Sales Estimate Current Quarter

209

Average Sales Estimate Next Quarter

262

Fair Value

Quality Score

22

Growth Score

55

Sentiment Score

86

Actual DrawDown %

2.8

Max Drawdown 5-Year %

-61.7

Target Price

249.89

P/E

Forward P/E

48.09

PEG

P/S

22.01

P/B

P/Free Cash Flow

EPS

-4.97

Average EPS Est. Cur. Y​

-2.46

EPS Next Y. (Est.)

2.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-54.94

Relative Volume

0.65

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

1.1

EBIT Estimation

57.7
Ascendis Pharma A/S
Sector: Healthcare
Industry: Biotechnology
Employees: 1017
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today
news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance
stock history ASND – Ascendis Pharma A/S invest stock market
stock prices ASND premarket after hours
ticker ASND fair value insiders trading